EIF2AK3 and melanoma: We confirmed differential vemurafenib activity in BRAF mutant (A375, SK-Mel-28) and non-mutant (SK-Mel-147) melanoma cell lines with regard to growth and pERK inhibition occurring only in BRAF mutant cells (Fig 1A and Supplemental Fig. 1A).